

IN THE SPECIFICATION

Please insert the following paragraph to follow immediately after the title:

a¹ This application claims priority under 35 U.S.C. § 119(e) of provisional application serial no. 60/144,736, filed July 21, 1999.

Please amend the specification as follows (pursuant to rule 1.121, a marked-up version of each amended paragraph is attached in a separate document):

In the "Brief Description of the Drawings", at page 6, lines 6-8, please amend the description of Figure 4D to read as follows:

a² Figure 4D depicts a new motif MIVVKDESSP [SEQ ID NO: 15] shared between DRAP and other recombination-related proteins as identified through cross reactivity with anti-DRAP antibodies and sequence comparison. Depicted are motif sequences from mouse and human RAD 51, LLIVDS [SEQ ID NO: 23]; yeast RAD 51 and DCM 1, LIVVDS [SEQ ID NO: 24]; E. coli REC A, VIVVDS [SEQ ID NO: 25]; FLP recombinase, MIALKDETNP [SEQ ID NO: 26]; T4 Gene 32 protein, ILVVKDPAAP [SEQ ID NO: 27], MIAVDVEMGE [SEQ ID NO: 28] and KGFSSE [SEQ ID NO: 29]; and human topoisomerase I, IKDEP [SEQ ID NO: 30], KDGSSE [SEQ ID NO: 31] and GFSSP [SEQ ID NO: 32].

In the description of Example 8 which begins on page 41, please amend the first paragraph immediately following the section heading "*Injection of DRAP and c-kit Oligos*", which bridges pages 41-42, to read as follows:

a³ DRAP was coinjected into male pronuclei of fertilized mouse eggs with c-kit 5'P-containing oligonucleotide, [SEQ ID NO:9] at a concentration of 10:1 molar ratio of DRAP to oligonucleotide. In this experiment approximately 500,000 molecules of DRAP and